Shionogi Company Limited

Sumitomo Chemical Company, Limited

Sumitomo Chem.co., Ltd.

Hiroyuki Kai

Akira Takase

Kuniyoshi Nishida

Moriyasu Masui

Takami Murashi

Michio Masuko

Tomoyuki Ogawa

Kazuo Ueda

Ichiro Ishizuka

Masahiko Nagai

Shoji Shinomoto

Takeshi Endoh

Shiro Ueda

Takayuki Kameyama

Tsuneo Iwakawa

Shinzaburo Sumimoto

Toshikazu Ohtsuka

Kinya Ide

Koji Hanasaki

Toru Yamada

Koji Masuda

Hideyuki Takenaka

Akihiko Nakamura

Yukio Tada

Tsuyoshi Hasegawa

Naotake Kobayashi

Yujiro Kiyoshima

Mikio Sasaki

Katuhisa Masumoto

Shuichi Sugiyama

Yoshiyuki Taoda

Yoshiharu Hiramatsu

Noriyuki Kurose

Eiichi Kojima

Akira Murabayashi

Tohru Horiguchi

Koichi Morita

Kentaro Asahi

Miho Oohara

Yoshito Ueyama

Shunji Shinohara

Keiichiro Hirai

Takuya Shintani

Akira Iida

Hiroyuki Tobinaga

Satoru Tanaka

Yuki Murakami

Yasuhiko Fujii

Yuki Ogata

Katsumi Koike

Yasuhide Morioka

Minoru Tomida

Azusa Nozu

Ken'ichioh Nakamura

Sumimoto Shinzaburo

Sae Jikihara

Toshikatsu Maki

Ken'ichiroh Nakamura

A crystal of a 1,3,5-triazine derivative or a solvate thereof, and a method for producing the same are provided. The present invention relates to a crystal of a compound represented by Formula (I) or a solvate thereof:

Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same

Provided are a novel compound having an antagonistic activity for the P2Xreceptor, and a pharmaceutical composition having an antagonistic activity for the P2Xreceptor. A compound represented by Formula (I): wherein Zis C(R) or the like; Ris a hydrogen atom or the like; Zis C(R)(R) or the like; the dashed line represents the presence or absence of a bond; when the dashed line represents the presence of a bond, then Ris absent; Rand Rare each independently a hydrogen atom or the like; Ring Q is a substituted or unsubstituted 5-membered non-aromatic heterocycle or the like; Yis O or the like; Ris a group represented by the formula: &#x2014;(C(R)(R))&#x2014;R; Ris a hydrogen atom or the like; Rand Ris each independently a hydrogen atom or the like; Ris substituted or unsubstituted aromatic carbocyclyl or the like; X is N(R) or the like; Ris a hydrogen atom or the like; Ris substituted or unsubstituted aromatic carbocyclyl or the like; n is an integer from 0 to 4; and m is an integer from 0 to 4, or a pharmaceutically acceptable salt thereof.

Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same

A compound represented by Formula (I): wherein or the like,Yis O or the like; Zis C(R) or N; Zis C(R) or the like; Zis C(R) or the like; R, Rand Rare each independently a hydrogen atom or the like; Ris substituted or unsubstituted aromatic carbocyclyl or the like; R, R, Rand Rare each independently a hydrogen atom or the like; X is N(R) or the like; Ris a hydrogen atom or the like; Ris or the like,Ring B is a 6-membered aromatic carbocycle or the like; Rand Rare each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3,or a pharmaceutically acceptable salt thereof.

6-membered heterocyclic derivatives and pharmaceutical composition comprising the same

Provided are a novel compound having an antagonistic activity for the P2Xreceptor, and a pharmaceutical composition having an antagonistic activity for the P2Xreceptor. The compound represented by Formula (I): wherein the symbols are defined in the specification, or a pharmaceutically acceptable salt thereof.

A compound represented by Formula (I): wherein or the likeYis O or the like; Zis C(R) or N; Zis C(R) or the like; Zis C(R) or the like; R, Rand Rare each independently a hydrogen atom or the like; Ris substituted or unsubstituted aromatic carbocyclyl or the like; R, R, Rand Rare each independently a hydrogen atom or the like; X is N(R) or the like; Ris a hydrogen atom or the like; Ris or the likeRing B is a 6-membered aromatic carbocycle or the like; Rand Rare each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3,or a pharmaceutically acceptable salt thereof.

The present invention provides novel compounds having a P2Xand/or P2Xreceptor antagonistic activity. A compound of Formula (I): wherein Rand R, and Rand Rare taken together to form oxo or the like; Rand Rare hydrogen or the like; n is 1 or the like; Ris aryl or the like; s and s' is 0 or the like; Rand R&#x2032; are halogen or the like; Rand Rare hydrogen, alkyl or the like; u is 1 to 4; Ris hydrogen or the like,or its pharmaceutically acceptable salt.

Aminotriazine derivative and pharmaceutical composition comprising the same

The present invention provides novel compounds having a P2Xand/or P2Xreceptor antagonistic activity. A compound of Formula (I): wherein Rand R, and Rand Rare taken together to form oxo or the like; Rand Rare hydrogen or the like; n is 1 or the like; Ris aryl or the like; s and s' is 0 or the like; Rand R&#x2032; are halogen or the like; Rand Rare hydrogen, alkyl or the like; u is 1 to 4; Ris hydrogen or the like, or its pharmaceutically acceptable salt.

The present invention provides novel compounds having a P2Xand/or P2Xreceptor antagonistic effect. A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): whereinRand Rare taken together to form a bond; Rand Rand/or Rand Rare taken together to form oxo or the like; Ris hydrogen, substituted or unsubstituted alkyl or the like;Ris &#x2014;(CRR)&#x2014;R; Rand Rare hydrogen, substituted or unsubstituted alkyl or the like; Ris substituted or unsubstjtuted cycloalkyl or the like; n is an integer of 1 to 4; &#x2014;Ris &#x2014;X&#x2014;R; &#x2014;X&#x2014; is &#x2014;O&#x2014;, &#x2014;S&#x2014; or the like; Ris substituted or unsubstituted cycloalkyl or the like,or its pharmaceutically acceptable salt or a solvate thereof.

Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same

The present invention provides a novel P2Xand/or P2Xreceptor antagonist. A compound represented by the formula (I): wherein R, Rand Rare,

Triazine derivative and pharmaceutical composition comprising the same

The present invention provides novel compounds having a P2Xand/or P2Xreceptor antagonistic effect, e.g. a compound of Formula (I): wherein wherein

Heterocyclic ring and carbocyclic derivative

The present invention provides novel compounds having a P2Xand/or P2Xreceptor antagonistic effect. A pharmaceutical composition having a P2Xand/or P2Xreceptor antagonistic effect comprising a compound of the formula (I): wherein

Heterocyclic derivative and pharmaceutical composition comprising the same

The present invention provides a novel P2Xand/or P2Xreceptor antagonist. A compound represented by the formula (I): 

The present invention provides a novel P2Xand/or P2X/receptor antagonist. A compound represented by the formula (I): wherein Zis optionally protected hydroxy, etc.; Zis &#x2014;C(&#x2550;O)&#x2014;, etc.; Zand Zare taken together &#x2550;O or &#x2550;S; t is an integer of 0 to 4; Rand Rare each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; Rand Rare each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; Ris substituted or unsubstituted alkyl, etc.; Ris substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.

Pyrolinone derivative and pharmaceutical composition comprising the same

The present invention provides a compound represented by the formula (I): wherein R, R, R, Z, Z, R, R, q, A and n are as defined in the description, a pharmaceutically acceptable salt or solvate thereof. The compound is useful as P2Xand/or P2X/receptor antagonist.

Pyrrolinone derivative and pharmaceutical composition comprising the same

Growing community of inventors

Osaka, Japan

Hiroyuki Kai